Interview with Zoe Helene, Founder of Cosmic Sister

So why do we think psychedelic stocks are the next big thing? Here is the story of how the Joe Rogan Podcast led one Tesla Investor to investing in psychedelic stocks and starting the channel: The Psychedelic Investor 🍄.

From MindMed (MMED/MMEDF) to Compass Pathways (CMPS) and other growth stocks in the psychedelic landscape, we aim to cover the developments in the psychedelic stocks field. Our main goal is creating a community where information can be shared and we can learn each other. So is investing in psychedelic stocks the future? Guess we’ll find out soon enough: together.

👍Like & Subscribe to join us on our journey to achieving Alpha Returns

Music: www.bensound.com
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#PsychedelicStocks #MindMed #JoeRogan #Tesla #ShroomStocks #MMED #CMPS #ThePsychedelicInvestor

When it comes to investing in psychedelic stocks such as MindMed (MNMD, MMED), Compass Pathways (CMPS), atai Life Sciences (ATAI), Cybin (CYBN) and more, even if we have a solid long term thesis, the short term is very volatile.

To sign up for the Psychedelic Stock Tips Newsletter, follow this link and scroll to the bottom of the page: https://psychedelicspotlight.com/about/

Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight

To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/

PS: THIS IS NOT INVESTING ADVICE, JUST MY OPINION.

In this video, I will discuss what to look out for, both the positives and the negatives, in the coming months. What are the catalysts? What are the risks?
The main thing to understand, is that the market cares more about short term profit than it does long term indicators. Right now, we are seeing psychedelic medicine clinical trials showing fantastic results, but we should not expect the market to react until we are closer to commercialization.
There are also many macro risks to be aware of, and general all around volatility. But we need to remember, short term swings do not affect the long-term thesis.

Links:
Awakn Phase 2 Ketamine Therapy for Alcohol Use Disorder:
https://psychedelicspotlight.com/ketamine-trial-alcohol-use-disorder-promising-results-awakn-life-sciences/

MAPS Phase 3 MDMD for PTSD Trial
https://psychedelicspotlight.com/first-phase-3-trial-mdma-assisted-therapy-ptsd/

Compass Pathways Phase 2b Psilocybin for Depression Trial
https://psychedelicspotlight.com/compass-pathways-largest-psilocybin-therapy-trial-ever-depressive-symptoms-rapidly-reduce/

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#PsychedelicStocks #MindMed #Cybin

Hey guys! Here’s the recap of MindMed’s (MMED / MNMD/ MMQ) Q1 conference call. They added lots of color on their different projects, and provided us with a lot of interesting new information. So, in this episode, we will cover a few topics. These are:

1. MindMed’s Mission
2. Their Talent acquisition
3. The Progress of their different clinical trials
4. The future

Timestamps:
0:00 – Intro
1:59 – MindMed’s Mission
4:36 – MMED’s talent acquisition
7:24 – MindMed’s clinical trial progress
10:48 – Psychiatry department : Project Lucy
14:17 – Addiction department : Project Layla (18MC)
18:33 – Pain department: Project Angie to treat pain card
22:56 – Neurology department: Project Flow using LSD microdosing to treat ADHD
23:43 – MindMed (MMED / MNMD) and its future plans

Enjoy!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @thepsychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video editing: @themyaholy
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #PsychedelicStocks #MNMD